Mebufotenin benzoate- Atai Beckley
Alternative Names: 5-MeO-DMT - Atai Beckley; 5-Methoxy-N-N-Dimethyltryptamine - Atai Beckley; BPL-002; BPL-003Latest Information Update: 19 Nov 2025
At a glance
- Originator Beckley Psytech
- Developer Atai Beckley
- Class Analgesics; Antidepressants; Behavioural disorder therapies; Ethers; Mood stabilisers; Small molecules; Tryptamines
- Mechanism of Action Serotonin receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alcoholism; Major depressive disorder
Most Recent Events
- 11 Nov 2025 Updated efficacy and safety data from a phase IIb study in patients with Major depressive disorder released by Atai Beckley
- 05 Nov 2025 ATAI Life Sciences has merged with Beckley Psytech to form Atai Beckley
- 17 Oct 2025 Mebufotenin benzoate- Beckley Psytech receives Breakthrough Therapy status for Major depressive disorder in USA